Founded in 1849, Pfizer is a multinational pharmaceutical company located in New York, NY. The company was founded by two German entrepreneurs, Charles Erhart and his cousin Charles Pfizer. Currently, the company is headquartered on 42nd Street in Manhattan.
Relative strength rating
Despite the fact that Pfizer has been a top stock in recent years, it is not a buy right now. The stock is in a new consolidation and has not broken out of it yet.
Pfizer has a number of things going for it, including a patented respiratory syncytial virus vaccine that is the most comprehensive for elderly patients. It is also developing vaccines for newborns and pregnant women. The company is working in developed as well as emerging markets. It works in a variety of industries, including pharmaceuticals, cosmetics, and biotechnology.
The A+ Investor from AAII is a tool that can help you figure out which stocks to invest in. The tool offers intuitive A-F grades for five key investing factors.
The RSI has been in a bullish uptrend and has remained strong throughout the year. This means that momentum is likely to remain.
EPS is a key measurement of a company’s performance. Using an EPS rating can be a good way to gauge the relative performance of a stock against its peers. For instance, if a company has a higher EPS rating than its industry peers, that is a positive sign for its performance.
Pfizer stock currently has an EPS rating of 93 out of 99. This EPS score reflects a combination of growth and innovation. In addition to its traditional medicines, Pfizer has developed a number of innovative vaccines. These include the recently approved Myfembree, a once-daily pill for endometriosis, and an experimental drug for the treatment of cardiomyopathy.
The Pfizer name is well-known. The company has been in business since 1849 and has become one of the largest and most successful pharmaceutical companies in the world. As such, it has a portfolio of innovative products that are used across a wide variety of healthcare segments, including internal medicine, vaccines, and small molecules.
Investing in Pfizer is an attractive option for ESG investors looking to gain exposure to the health sector. With over 50 billion in annual sales, Pfizer is one of the largest pharmaceutical companies in the world. The company’s strategy is anchored in the Purpose Blueprint, which outlines the strategic direction of the company.
Pfizer leads the industry in access-to-medicine governance. The company has comprehensive access strategies for all of its products. It also has robust compliance controls and offers financial rewards. The company’s executive management team has the highest responsibility for access. The company’s board also oversees the company’s access strategy.
Pfizer publicly discloses its commitments to global public health and to eradicating malaria. The company has also engaged in scaling up four inclusive business models. These include the use of a digital health platform to improve healthcare in remote areas and a dengue reduction program.
Two important launches in 2023
Among the major advances announced by Pfizer Inc. in the past year was the progress of its 20-valent pneumococcal conjugate vaccine candidate (20vPnC), which was recently awarded a Breakthrough Therapy Designation from the FDA. The company also shared positive Phase 3 data for a HER2-Antibody Drug Conjugate (HER2-ADC) for breast cancer. The new drug is targeting HER2+ tumors with a very stable site-specific conjugated auristatin payload.
Another key advancement was the launch of Pfizer’s COVID-19 vaccine with BioNTech SE. The two companies began a Phase 2 study in July 2022. The company expects to enroll patients in five clinical trials in 2023. Currently, the COVID-19 vaccine is available free to the U.S. government and people who have private health insurance.
Besides the vaccine, Pfizer has several other candidates with blockbuster potential. Its HER2-ADC has a very impressive response rate in HER2+ breast cancer, and the company plans to launch a multiple myeloma bispecific antibody. In addition, the company has data for a clesacostat/ervogastat combination in a liver biopsy study.
Vaccine for respiratory syncytial virus
Among the many pharmaceutical companies in the United States, Pfizer has been at the forefront of developing and testing an experimental vaccine for the respiratory syncytial virus (RSV). The company plans to submit a biologics license application to the FDA by the end of the year for its RSVpreF (PF-0692831) vaccine. This vaccine is designed to help prevent lower respiratory tract disease caused by RSV in people aged 60 and older.
Although the vaccine is still in its early development, it may prove to be a game changer in the fight against RSV. The vaccine could spare millions of infants from a life-threatening illnesses. It may also reduce the lung damage caused by RSV.
The benefits of the Pfizer RSV vaccine are numerous. The company claims that the vaccine is effective at reducing the severity of a child’s RSV infection and may save some of the approximately 120,000 children who die from the disease each year.